


REMARKS

Applicants hereby elect, without traverse, the invention of Group I, Claims 1 – 7, for further prosecution in the application.

Applicants further elect as the species, the compound of Example 2 on page 68 of the application, identified as (2S)-2-(3(S)-Acetylamino-3-(S)-sec-butyl)-2-oxo-pyrrolidin-1-yl)-N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-4-phenyl-butamide, and represented structurally below:




It is believed that all of the elected claims 1-7 read on this embodiment.

The application is believed to be in condition for allowance, and prompt, favorable action thereon is earnestly solicited. Should Examiner Royds feel that any other point requires consideration, then she is cordially invited to contact the undersigned.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000


John F. Levis
Attorney for Applicant
Reg. No. 34,210
Phone: 203-677-3782
Date: July 2, 2008